Alteogen Files Merger Securities Registration Statement for 600,477 New Shares Worth ₩156.9B

What happened

On 2026-10-14 Alteogen filed a securities registration statement (merger) with the Financial Services Commission. The securities are 600,477 registered common shares, with a total offering amount of ₩156,931,661,565 (about ₩156.9B).

Against 42,264,250 listed shares, the new shares equal about 1.4% of the current share count. The ₩156.9B amount equals about 1.7% of the market capitalization of ₩9.49T on 2026-10-13, and about 61.8% of trailing revenue of ₩254.0B. These are our own comparisons using the filed figures.

The excerpt covers the cover page and the start of the risk summary. The risks cited include global economic conditions, US tariff policy on patented drugs (a 15% rate applies to Korea) and interest rates. The excerpt does not name the merger counterparty, the merger ratio, the effective date or the effect on earnings. The cover page lists a second location, Alteogen Biologics, in Seoul, but the excerpt does not explain its role in the merger.

What it changes for the thesis

The previous report described strong fundamentals: revenue of ₩254.0B, a 47.2% operating margin and low borrowings of ₩3.2B. It also said the October 6 merger and rights offering filings were material but that their size was not in the data.

The filing partly fills that gap. The merger issues about 1.4% new shares, which is small relative to the share count. This does not change the earnings picture in the filed results. Still, the counterparty, purpose, financial impact and the terms of the four rights offering decisions remain unknown from the data given. The uncertainty flagged earlier is reduced but not resolved.

What it changes for the valuation

The model has no fair value estimate for this company, and the previous report had none, so there is no range to compare. Without a model estimate, the filing cannot be translated into a per-share value change.

The share price closed at ₩224,500 on 2026-10-13, down 49.4% over one year and close to the 52-week low of ₩217,500. Current multiples are P/E 49.1, P/B 17.7 and P/S 37.4, lower than the previous report's 64.1, 23.1 and 48.7 mainly because of the lower price. Samsung Biologics trades at P/E 40.2 and Celltrion at 15.7, so Alteogen remains higher than the peers with data. Any dilution from the new shares would be small by count, but the effect on earnings and equity cannot be assessed from the data.

Closing view

The registration statement shows a merger issuance that is modest in share count, about 1.4%, and in value, about ₩156.9B. The reported financial strength is unchanged, and the multiples remain high compared with peers. Key facts that would let a reader judge the deal, such as the counterparty, the ratio, the rationale and the rights offering terms, are not available in the data. The evidence therefore narrows the uncertainty without removing it, and it supports no conclusion about the future share price.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

• Securities registration statementOct 14, 2026
• Investor relations (IR) eventOct 8, 2026
• Determination of Shareholder Register Closure Period or Record DateOct 6, 2026
• Merger decisionOct 6, 2026
• Added attachment: Merger decisionOct 6, 2026
• Rights offering (paid-in capital increase) decisionOct 6, 2026
• Rights offering (paid-in capital increase) decisionOct 6, 2026
• Rights offering (paid-in capital increase) decisionOct 6, 2026
• Rights offering (paid-in capital increase) decisionOct 6, 2026
• Investor relations (IR) eventSep 21, 2026
• Major management matter relevant to investorsSep 2, 2026
• Major management matter relevant to investorsAug 31, 2026
• Daily prices up to 2026-10-13
• Financial statements, trailing 12 months as of H1 2026

Report history

1. Oct 14, 2026Update noteM&A / restructuringAlteogen Files Merger Securities Registration Statement for 600,477 New Shares Worth ₩156.9B
2. Oct 13, 2026InitiationAlteogen: Sharp Profit Growth Meets a 49.8% One-Year Share Price Decline and New Merger and Rights Offering Filings